Nanodropper, Inc. v. J4J, LLC: Voluntary Dismissal in Ophthalmic Drug Delivery Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Nanodropper, Inc. v. J4J, LLC |
| Case Number | 0:24-cv-01475 (D. Minn.) |
| Court | U.S. District Court for the District of Minnesota |
| Duration | Apr 2024 – Jul 2024 94 Days |
| Outcome | Voluntary Dismissal (Plaintiff Withdrawal) |
| Patents at Issue | |
| Accused Products | J4J, LLC’s PRECISION DROPPER |
Case Overview
The Parties
⚖️ Plaintiff
Minnesota-based medical device company focused on reducing eyedrop waste and improving dosing precision with its NANODROPPER® device.
🛡️ Defendant
Company associated with the competing PRECISION DROPPER product in the ophthalmic drug delivery market.
Patents at Issue
This case involved **U.S. Patent No. 10,695,216 B2**, covering technology in the ophthalmic drug delivery device space — specifically, innovations related to precision eyedrop dispensing that reduce drop volume and improve dosing consistency. Patent holders in this space typically assert claims covering device geometry, fluid mechanics, or adapter mechanisms designed to interface with standard eyedrop bottles.
- • US 10,695,216 B2 — Precision eyedrop dispensing technology
Designing a similar medical device?
Check if your ophthalmic device design might infringe this or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case terminated via a Notice of Voluntary Dismissal, filed by Nanodropper, Inc. as plaintiff on July 25, 2024. No damages were awarded, no injunctive relief was granted, and no court ruling on the merits of infringement or patent validity was issued. Specific terms underlying the decision to dismiss — whether a confidential settlement, licensing agreement, or strategic withdrawal — are not disclosed in publicly available case records.
Key Legal Issues
The verdict cause is classified as an Infringement Action, meaning Nanodropper initiated this proceeding to enforce its patent rights under 35 U.S.C. § 271 against J4J, LLC’s PRECISION DROPPER. The voluntary dismissal, however, means no judicial findings regarding literal infringement, the doctrine of equivalents, or patent validity were produced.
Voluntary dismissals in patent cases of this duration typically reflect one of several strategic dynamics: pre-litigation settlement or licensing, plaintiff’s reassessment of claim strength, defendant’s design-around, or a commercial resolution outside court. Without court-issued claim construction orders or summary judgment rulings, the legal record from this case does not establish precedent regarding the scope or validity of U.S. Patent No. 10,695,216 B2.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in the ophthalmic drug delivery device market. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in this technology space
- See which companies are most active in ophthalmic device patents
- Understand claim construction patterns for precision droppers
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Precision eyedrop dispensers
1 Patent at Issue
In ophthalmic drug delivery space
Design-Around Options
Available for most claims
✅ Key Takeaways
Voluntary dismissal within 94 days reflects early-stage resolution dynamics common in single-patent, direct-competitor disputes.
Search related case law →No precedential claim construction issued — U.S. Patent No. 10,695,216 B2 scope remains judicially untested.
Explore precedents →Rule 41 dismissal terms (with or without prejudice) are critical to assess for potential refiling risk.
Understand dismissal rules →Nanodropper’s enforcement posture confirms active patent monetization strategy in the ophthalmic device space.
Monitor Nanodropper’s portfolio →Licensing conversations may be the practical resolution pathway in this technology category.
Explore licensing trends →Frequently Asked Questions
The case involved U.S. Patent No. 10,695,216 B2 (Application No. US16/255,152), covering ophthalmic drug delivery device technology related to Nanodropper’s precision eyedrop dispensing products.
The specific basis for voluntary dismissal was not publicly disclosed. Common reasons include confidential settlement, licensing resolution, design-around by the defendant, or plaintiff’s strategic reassessment of claim strength after early case development.
While no precedential ruling was issued, the case signals active enforcement of precision dropper patents. Competitors and new market entrants in the ophthalmic adapter space should prioritize FTO clearance against Nanodropper’s IP portfolio.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- U.S. Patent No. 10,695,216 B2 — USPTO/Google Patents
- Case Docket No. 0:24-cv-01475 — PACER Federal Court Records
- U.S. District Court for the District of Minnesota — Patent Litigation Procedures
- Cornell Legal Information Institute — 35 U.S.C. § 271
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.